INTRODUCTION {#s1}
============

Coffee is among the most consumed beverages worldwide: in Europe, the geographic area showing the highest coffee consumer in the world, people are reported to drink 725 million cups of coffee every day \[[@R1]\]. In light of its wide consumption, it is an important public health goal to assess whether coffee has protective or detrimental effects against cancer risk.

Current evidence from epidemiological and experimental studies suggests that coffee consumption may exert beneficial effects towards non-communicable diseases \[[@R2]\]. In particular, coffee consumption has been associated with decreased risk of cardio-metabolic conditions, including metabolic syndrome \[[@R3]\], diabetes \[[@R4]\] and cardiovascular disease \[[@R5]\]. Research on cancer risk showed more controversial findings: a summary of evidence reported that coffee could have a protective role against the development of various cancers, including liver, colorectal, endometrial, oral, melanoma, and prostate cancer among others \[[@R6]--[@R12]\]. However, other revision of existing literature reported contrasting results \[[@R13], [@R14]\]: this conclusion was based on a dose-response meta-analysis of 10 cohort studies, and the relative risk (RR) for an increment of 1 cup/day appeared to be not significantly associated with risk of overall cancers \[[@R15]\]. Numerous confounders and effect modifiers can have a role in assessing the relationship between coffee consumption and health outcomes: for instance, recent meta-analyses on coffee consumption and various health outcomes pointed out that the ambiguous results on cancer mortality and hypertension were due to the modifying effect of smoking \[[@R16], [@R17]\].

Ovarian cancer has a major epidemiological and social burden for women worldwide: in 2012, women with a diagnosis of ovarian cancer occurred in the last 5 years were over 587,000 and 157,000 worldwide and in Europe, respectively \[[@R18], [@R19]\]. In 2013, deaths accounted for ovarian cancer were about 158,000 worldwide, together with over 4 million disability adjusted life years (DALYs); such figure significantly increased from 1990 (2.7 million DALYs) and poses ovarian cancer as the worldwide 12th contributor of death and disability among cancers \[[@R20]\].

The evidence on the association between coffee drinking and the risk of ovarian cancer is quite limited and inconsistent. Results of a meta-analysis of prospective cohort studies revealed a non-significant positive association between coffee drinking and risk of ovarian cancer \[[@R21]\]. However, more recent data has been published and comprehensive summary of evidence is lacking. Thus, the aim of this study is to update current evidence on the association between dietary coffee consumption and risk of ovarian cancer testing also the dose-response relation.

METHODS {#s2}
=======

We performed a meta-analysis of prospective cohort studies following Meta-Analysis of Observational Studies in Epidemiology (MOOSE) protocols throughout design, execution, analysis and reporting stages ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}).

Search strategy {#s2_1}
---------------

To collect and critically review the evidence, we performed a comprehensive literature search in PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>) and EMBASE (<http://www.embase.com/>) databases, from the earliest available online indexing year to March 2017. The search was limited to studies published in English. Search terms included the following: (coffee OR caffeine OR beverages) AND (ovarian) AND (cancer OR carcinoma OR neoplasm) ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Titles and abstracts of all identified studies were screened by two members of the team. Studies were eligible for inclusion in the meta-analysis if they met the following inclusion criteria: 1) the study had a prospective design; 2) the exposure of interest was coffee consumption; 3) the outcome was ovarian cancer incidence; 4) the investigators reported relative risks with 95% confidence intervals for 3 or more quantitative categories of coffee consumption. When discrepancies over inclusion arose, inclusion criteria were assessed to reach a consensus. Reference lists of included manuscripts were also screened for any additional study not previously identified. When duplicate reports on the same cohort were identified, we included the one that provided the largest number of cases (or entire cohort) or with the longest follow-up for each endpoint of interest.

Data extraction {#s2_2}
---------------

Data were abstracted from all identified studies using a standardized extraction form. Information was extracted from each study and consisted of: 1) first author name; 2) year of publication; 3) study cohort name; 4) country; 5) number of participants; 6) gender of participants; 7) age range of the study population at baseline; 8) categories of consumption; 9) coffee type; 10) follow-up period; 11) endpoints and cases; 12) distributions of cases and person-years, HRs, and 95% CIs for all categories of exposure; 13) covariates used in adjustments. Extraction of data was performed independently by two authors. Discrepancies were discussed and resolved by consensus. The quality of included studies was assessed according to the Newcastle-Ottawa Quality Assessment Scale \[[@R22]\].

Statistical analysis {#s2_3}
--------------------

Highest *versus* lowest and dose-response meta-analyses were performed to determine the relationship between coffee intake and ovarian cancer risk. The most fully adjusted RRs/HRs with 95% CI for all categories of exposure were extracted. Random-effects models were used to calculate pooled effects, wherein HRs were deemed as equivalent to relative risks (RRs) \[[@R23]\]. Heterogeneity was assessed through the *I*^*2*^ statistic, which estimates the fraction of variance that is due to heterogeneity and by *Q* test. The level of significance for the *Q* test was defined as *P* \< 0.10. The values of *I*^*2*^ statistic ≤25%, 25--50%, 50--75%, and \>75% indicated no, small, moderate, and significant heterogeneity, respectively. The stability of the results and potential sources of heterogeneity were examined in a sensitivity analysis excluding one study at a time and in subgroup analysis according to menopausal status and geographical area. Included studies did not provide datasets of stratified analysis to test for potential confounders/effect modifiers, such as smoking or BMI. Therefore, subgroup analyses were only performed according to adjustment for smoking status, BMI, education level and alcohol consumption. Publication bias was evaluated by a visual investigation of funnel plots for potential asymmetry.

To examine linear and non-linear relationship between coffee intake and risk of ovarian cancer, random-effects dose-response meta-analysis was used. We extracted data on the amount of coffee intake, distributions of cases and person-years (when available), and RRs/HRs with 95% CIs for ≥3 exposure categories. In each study across categories of consumption, the mean or median intake of coffee was assigned to the corresponding RR/HR with the 95% CI. When originally in article the range of coffee intake was reported , the midpoint of the range was selected . When the highest category was open ended, we assumed the width of the category to be the same as the adjacent category. When the lowest category was open ended, we set the lower boundary to zero. Random-effects dose-response meta-analysis was performed in two-stages. In the first stage the method reported by Greenland and Orsini (that is, GLS) was used to calculate study-specific slopes (generalized least-squares, GLS) on the basis of results across categories of coffee intake taking into account the correlation within each set of retrieved HRs \[[@R24], [@R25]\]. Model of restricted cubic splines with 3 knots at fixed percentiles (25%, 50%, and 75%) of the distribution was applied in non-linear dose-response. \[[@R26]\]. We combined the coefficients that had been calculated within each study by performing random-effects meta-analysis with DerSimonian and Laird estimator of between study variance (in linear dose-response meta-analysis) or estimator received by using the method of moments (in non-linear dose-response meta-analysis). We calculated an overall *P*-value by testing that the 2 regression coefficients were simultaneously equal to zero. We then calculated a *P*-value for non-linearity by testing that the coefficient of the second spline was equal to zero. All analyses were performed with R software version 3.0.3 and we mainly used dosresmeta package (Development Core Team, Vienna, Austria).

RESULTS {#s3}
=======

Study characteristics {#s3_1}
---------------------

We identified a total of 1,340 studies, of which 1,223 were excluded after review of title, and 104 on the basis of abstract (Figure [1](#F1){ref-type="fig"}). Of the remained thirteen publications, four were not included for the following reasons: 1) the article did not provide relative risks (or similar risk measures) and corresponding confidence intervals; 2) the study provided less than three exposures of coffee consumption; 3) the article reported on gene polymorphism. For the analysis on the association between coffee consumption and ovarian cancer risk, nine studies were eligible \[[@R13], [@R27]--[@R34]\], of which one was a multi-center study \[[@R27]\]. Studies included in the analysis comprised 787,076 participants and 3,541 ovarian cancer cases. Five studies were conducted in Europe \[[@R27], [@R28], [@R30], [@R31], [@R33]\] and four in USA \[[@R13], [@R29], [@R32], [@R34]\]. Three studies provided risk estimates for postmenopausal status \[[@R13], [@R29], [@R33]\], and three for caffeinated and decaffeinated coffee consumption (27, 29, 34). The follow-up in prospective studies ranged from about 11 to 24 years, and the age range at study baseline was 25-76 years. Characteristics of the studies included in the meta-analysis are provided in Table [1](#T1){ref-type="table"}.
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###### Characteristics of the cohort studies included in the meta-analysis

  Author, year    Cohort name, country   Years of study, follow-up     Cases; total population   Age range   Adjustments
  --------------- ---------------------- ----------------------------- ------------------------- ----------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Larsson 2005    SMC, Sweden            1987--2004, 15.1y (mean)      301; 61,057               40--76y     Age in months, BMI, education, parity, oral contraceptive use, and intakes of total energy, fruit, vegetables, milk, and tea.
  Silvera 2007    NBSS, Canada           1980--2000, 16.4y (mean)      264; 48,776               40--59y     Age, smoking history, pack-years of smoking, alcohol intake, education, BMI, parity, participation in vigorous physical activity, menopausal status, oral contraceptive use, energy intake, lactose intake, study center, and randomization group.
  Steevens 2007   NLCS, Netherlands      1986--1999, 13.3y             280; 62,573               55--69y     Age, use of oral contraceptives, parity, cigarette smoking, tea.
  Lueth 2008      IWHS, USA              1986--2004, 18y (maximum)     266; 29,060               55--69y     Age, smoking, BMI, age at menopause, parity, oral contraceptive use, education level, physical activity, and total energy intake.
  Tworoger 2008   NHS, USA               1980--2004, 24y (maximum)     507; 80,253               30--55y     Age, parity, oral contraceptive use, postmenopausal hormone use, tubal ligation, smoking status, and BMI.
  Nilsson 2010    VIP, Sweden            1985--2007, 15y (maximum)     71; 32,178                30--60y     Age, sex, BMI, smoking, education, recreational physical activity.
  Braem 2012      EPIC, Europe           1992--NA; 11.7y (median)      1,244; 330,849            25--70y     Center, age, parity, oral contraceptive use, BMI, smoking status, alcohol consumption, total energy intake, duration of breastfeeding, menopausal status, height, educational level.
  Hashibe 2015    PLCO, USA              1992--2011; 13y (maximum)     162; 50,563               55--74y     Age, sex, race, education, smoking status, smoking frequency, smoking duration, time since stopping smoking for past smokers, and drinking frequency.
  Lukic 2016      NOWAC, Norway          1991--2013; 13.1y (average)   446; 91,767               30--70y     Menopausal status at baseline, smoking status, age at smoking initiation, number of pack-years smoked, duration of education, BMI, physical activity level, use of oral contraceptives, alcohol consumption, number of children, use of hormone replacement therapy, and maternal history of breast cancer.

Summary relative risk for highest versus lowest category of coffee consumption

The summary risk of ovarian cancer for highest *versus* lowest category of coffee consumption was RR = 1.06, 95% CI: 0.89, 1.26, with no evidence of heterogeneity *I*^*2*^ = 25%, *P* = 0.24 (Figure [2](#F2){ref-type="fig"}). No publication bias was found after visual inspection of funnel plot ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}) Two cohorts, NOWAC and VIP were excluded from the main analysis, as part of their cases are included in the multicentre study EPIC. However, an alternative analysis was performed by including this cohorts and excluding EPIC study; the relative risk was RR = 1.05, 95% CI: 0.88, 1.26; *I*^*2*^ = 20%, *P* = 0.27. Similarly, when taking into account menopausal status, no association between coffee consumption and ovarian cancer risk was found, and RR = 1.15, 95% CI: 0.92, 1.45; *I*^*2*^ = 0%, *P* = 0.87 (Table [2](#T2){ref-type="table"}). Finally, no significant differences were found for coffee type or adjustment for potential confounders (Table [2](#T2){ref-type="table"}).
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###### Subgroup analyses of studies reporting risk of ovarian cancer for the highest *versus* lowest (reference) category coffee consumption

  Subgroup                      No. of datasets   RR (95% CI)         *I*^2^   *P*~heterogeneity~
  ----------------------------- ----------------- ------------------- -------- --------------------
  Total                         7                 1.06 (0.89, 1.26)   25%      0.24
  Geographical area                                                            
   North America                4                 1.11 (0.79, 1.56)   62%      0.05
   Europe                       3                 1.05 (0.85, 1.32)   0%       0.98
  Menopausal status                                                            
   Postmenopausal               3                 1.15 (0.92, 1.45)   0%       0.87
   Premenopausal                0                 NA                  NA       NA
  Coffee type                                                                  
   Caffeinated                  3                 1.09 (0.70, 1.68)   78%      0.01
   Decaffeinated                3                 0.89 (0.66, 1.20)   0%       0.99
  Adjusted for smoking                                                         
   No                           1                 1.02 (0.62, 1.69)   NA       NA
   Yes                          6                 1.07 (0.88, 1.31)   37%      0.16
  Adjusted for BMI                                                             
   No                           2                 1.13 (0.87, 1.45)   0%       0.76
   Yes                          5                 1.05 (0.81, 1.36)   46%      0.12
  Adjusted for education                                                       
   No                           2                 0.89 (0.62, 1.27)   55%      0.14
   Yes                          5                 1.17 (0.97, 1.41)   0%       0.69
  Adjusted for alcohol intake                                                  
   No                           4                 0.96 (0.76, 1.22)   26%      0.26
   Yes                          3                 1.18 (0.95, 1.47)   0%       0.40

Dose-response meta-analysis {#s3_2}
---------------------------

Eight studies \[[@R13], [@R28]--[@R34]\] were included in dose-response meta-analysis of prospective studies on coffee consumption and ovarian cancer risk, three of which provided risk estimates for postmenopausal individuals \[[@R13], [@R29], [@R33]\].

We found no evidence of association between coffee consumption and ovarian cancer risk in both analysis on total group of women (Figure [3](#F3){ref-type="fig"}, Table [3](#T3){ref-type="table"}) and when considering only postmenopausal individuals.
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###### Dose-response meta-analysis of prospective cohort studies on coffee consumption and ovarian cancer risk

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                   No. of\     Coffee intake (cups/day)   *I*^2^ (%)          *P*~heterogeneity~   *P*~non-linearity~                                                                                                  
                   datasets\                                                                                                                                                                                           
                   (no. of\                                                                                                                                                                                            
                   studies)                                                                                                                                                                                            
  ---------------- ----------- -------------------------- ------------------- -------------------- -------------------- ------------------- ------------------- ------------------- ------------------- ------- ------ ------
  Total analysis                                                                                                                                                                                                       

  Non-linear       8 (8)       Ref.                       1.02 (0.93, 1.12)   1.04 (0.89, 1.21)    1.05 (0.88, 1.25)    1.06 (0.88, 1.28)   1.07 (0.86, 1.34)   1.08 (0.82, 1.41)   1.09 (0.79, 1.50)   --      0.55   0.85

  Linear           8 (8)       Ref.                       1.01 (0.97, 1.05)   1.02 (0.95, 1.10)    1.04 (0.92, 1.16)    1.05 (0.90, 1.22)   1.06 (0.88, 1.28)   1.07 (0.85, 1.35)   1.09 (0.83, 1.42)   32.91   0.17   NA

  Postmenopausal                                                                                                                                                                                                       

  Non-linear       3 (3)       Ref.                       1.06 (0.89, 1.26)   1.12 (0.84, 1.48)    1.15 (0.85, 1.56)    1.19 (0.89, 1.59)   1.22 (0.91, 1.64)   1.26 (0.91, 1.73)   1.29 (0.90, 1.86)   --      0.86   0.79

  Linear           3 (3)       Ref.                       1.04 (0.98, 1.09)   1.08 (0.97, 1.19)    1.12 (0.95, 1.30)    1.16 (0.94, 1.42)   1.20 (0.93, 1.55)   1.24 (0.91, 1.70)   1.29 (0.90, 1.85)   --      0.90   NA
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DISCUSSION {#s4}
==========

In this large meta-analysis of prospective cohort studies, we did not find any association of consumption of total, caffeinated, and decaffeinated coffee with risk of ovarian cancer. Despite a large number of studies suggested that an inverse relationship of coffee consumption and cancer risks may be mediated by various mechanisms, such as reduction of oxidative stress and DNA damages, detoxification of carcinogens, inhibition of carcinogenesis, and induction of apoptosis \[[@R35]--[@R38]\], a clear association with ovarian cancer risk could not be assessed. Coffee contains thousands of bioactive components including polyphenols, caffeine, diterpens and melanoidins, which have been shown to reduce oxidative stress and exert anti-cancerogenic properties \[[@R39], [@R40]\]. Dietary polyphenol intake has been associated lower risk of certain cancers and mortality in meta-analysis on prospective cohort studies \[[@R41], [@R42]\]. A protective effect of polyphenols could be exerted through an indirect action and through triggering defence mechanisms, carcinogenic detoxification, and activation or suppression of onco-suppressors and proto-oncogenes, respectively \[[@R43]--[@R45]\]. Additionally, it has been demonstrated that coffee intake improves metabolic features, both in women and men, which in turn could affect the association between cardio-metabolic conditions and certain cancers related to impaired metabolism and hormonal homeostasis \[[@R3], [@R46]--[@R49]\]. However, the results of the present meta-analysis showed that it is not likely a direct association between coffee consumption and ovarian cancer. A possible reason related to lack of effects of its polyphenol content may depend on their bioavailability \[[@R50]\]; in fact, it is still questionable which are the polyphenol metabolites reaching the target tissues, what is their amount, and whether they can actually exert any protective effects specifically on the ovarian cells \[[@R51]\].

Another reason for lack of association retrieved is potential confounding effect of other foods. Coffee consumption might be associated with unhealthy habits (i.e., higher alcohol intake. smoking), which in turn could be related to higher risk of cancers due to a synergistic effect of many functional components rather than an individual food or beverage \[[@R52]\]. Moreover, it has been suggested that polyphenols (including those contained in coffee) may be effective against multiple targets in cancer development and progression especially whether in combination with other polyphenols or micronutrients, such as antioxidant vitamins \[[@R53], [@R54]\]. In turn, the potential beneficial effects of coffee might be enhanced or counteracted by other dietary components, resulting in an overall null association depending on the overall diet rather than coffee alone. However, this hypothesis on the confounding effect of other foods on coffee should result in null results also for the association with other cancers, which in fact is not supported by other meta-analyses showing a decreased risk of certain cancers associated with higher coffee consumption: thus, either the confounding factors are strictly related to ovarian cancer risk or other explanation should be further investigated.

A major strength of our meta-analysis was the inclusion of cohort studies carried out with a prospective design, which implies detailed exposure and covariate assessment before the diagnosis of the outcome of interest (that is, ovarian cancer). Moreover, we performed a dose-response meta-analysis, which scientific value is higher than meta-analyses with exposure classified as high versus low, as it aims to investigate a possible dose-response relationship. However, the results of this study should be considered in light of some limitation. First, no stratified analysis was performed due to lack of available datasets, which prevented us from an in-depth analysis of potential confounders and effect modifiers, such as smoking status or body weight; despite our adjustment for smoking status, BMI index, education level and alcohol exposure, there is still a chance of unmeasured or residual confounding (e.g. menopausal status, that has not been considered in our analysis). Another limitation lies in the exposure assessment phase: the categories of low and high consumption varied across different studies, therefore overall estimates of high consumption might not be perfectly comparable; moreover, we don't have data on coffee brewing methods, preparation, cup size, and duration of consumption. Such differences, if properly addressed, could yield to significant results in specific exposure subgroups (for instance, when analysing the relationship between tea consumption and ovarian cancer risk, a positive association has been detected for all tea and for black tea, but not for green tea) \[[@R55]\]. Similarly, histological information on cancer-subtype, to differentiate among epithelial cancer histotypes ("high grade serous" versus "endometrioid" versus "clear cell"), included through a stratified analysis, could highlight different pathological pathways and diversified exposure-disease relationships.

In conclusion, the present study provided a robust assessment of the relationship between coffee consumption and ovarian cancer, which, coherently with previously published literature, appears null. Additional prospective cohort studies specifying also subgroup analyses by key variables (i.e., smoking status, type of coffee, etc.) are needed to further improve current knowledge on such topic.
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